Curi RMB Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

Curi RMB Capital’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-12,074	Closed	-$409K	–	997
2017 Q4	$409K	Buy	+12,074	New	+$337K	0.01%	650

Other funds holding ADMS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BWCA

Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Curi RMB Capital's ADMS Position: Q1 2018 in Review

Curi RMB Capital sold out of Adamas Pharmaceuticals (ADMS) in Q1 2018, closing a stake of 12,074 shares — an estimated $409K sold.

Curi RMB Capital first reported a position in ADMS in Q4 2017 and held it in 1 quarter. The position peaked at $409K in Q4 2017. 118 funds tracked by Wall St. Rank hold ADMS as of Q1 2018.

Curi RMB Capital reported no remaining Adamas Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Curi RMB Capital sold 12,074 Adamas Pharmaceuticals shares in Q1 2018, an estimated $409K.
Curi RMB Capital first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Curi RMB Capital's Adamas Pharmaceuticals position peaked at $409K in Q4 2017.
118 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2018.

Based on Curi RMB Capital's 13F filing for Q1 2018, filed 14 May 2018.